July 2024

MagnaPharm and Nordic Group B.V. have entered into a License and Distribution Agreement for Nordimet® in Romania. This collaboration leverages the strengths of both companies to bring enhanced healthcare solutions to patients across Romania and marks a significant step forward in the availability and accessibility of key medications in Romania, improving patients' access to suitable and effective treatment in the fields of rheumatology and dermatology. MagnaPharm, with proven track records and its strong existing network, is the ideal candidate to partner with Nordic Pharma and introduce products in CEE region. MagnaPharm is one of leading players in both Rx and OTC segments of the pharmaceutical market in CEE and offers an excellent platform to distribute and promote Nordic Pharma’ s brands.

“We are excited and very proud to announce our partnership with Nordic Pharma. For more than three decades, we are very successful in the marketing of branded Rx and premium OTC pharmaceuticals in the CEE region. Partnership with Nordic Pharma will help us to maintain and grow MagnaPharm’s strong presence in the CEE pharmaceutical market. We look forward to working with Nordic Pharma in achieving our milestones and increasing standards of care”.



Karol Michalak, CEO MagnaPharm

 ”Nordic Pharma is committed to making a sustainable impact on people`s lives across the globe. Expanding our alliance model to the new regions and countries is one of the key steps towards achieving this objective. We are looking forward to making our healthcare solutions even more accessible for the Romanian patients in partnership with one of the well-recognised pharmaceutical companies, Magna Pharm.”

Kirill Politkin, Director, General Export, Nordic Pharma

About MagnaPharm

MagnaPharm is a premier pharmaceutical and consumer healthcare service provider in Central & Eastern Europe. MagnaPharm is the partner of choice on the Central and Eastern Europe pharmaceutical market, offering a unique and full range of services on the distribution, marketing, sales, pharmaceutical retail, market access, pricing and medical services segments. MagnaPharm is going an extra mile to fulfil the demands of its reputable partners, multinational and specialty international pharmaceutical companies that have decided not to operate directly in CEE or already operating in CEE but outsourcing parts of their portfolios. MagnaPharm operates in all main CEE countries: Romania, Bulgaria, Poland, Hungary, Czech Republic, Slovakia, Serbia, Slovenia, Lithuania, Estonia, Latvia, Croatia, Bosnia, Albania, Montenegro, Kosovo and North Macedonia.

For more info about MagnaPharm, please visit: www.magnapharm.eu

About Nordic Pharma and Nordic Pharma’s portfolio

Nordic Pharma is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Ophthalmology, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.

Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.

For more information about Nordic Pharma, please visit https://www.nordicpharma.com